Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
59results about How to "For the purpose of treating tumors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Application of metal fullerene monocrystal nanoparticles in preparation of specific tumor vascular disrupting agent
ActiveCN104127872AStrong specificityUnrestricted microenvironmentEnergy modified materialsAntineoplastic agentsTumor vesselSurface charges
The invention discloses an application of metal fullerene monocrystal nanoparticles in preparation of a tumor vascular disrupting agent. The monocrystal nanoparticles are water-soluble metal fullerene nanoparticles with the surface charged with negative electricity, and have the particle size range of 50-250 nm; the nanomaterial can absorb and convert outside world radiation energy into heat energy, and the volume is expanded sharply when a temperature reaches a phase transition point. During treatment, a tumor-carried living organism is injected and given with the metal fullerene monocrystal nanoparticles; the metal fullerene monocrystal nanoparticles reach a tumor part through blood circulation, and are stranded at tumor pores and defective parts; under the action of the outside world radiation energy, the metal fullerene monocrystal nanoparticles accumulate heat, the temperature rises, and the volume is expanded sharply when the temperature exceeds the phase transformation critical point, so that morphological structures or functions of tumor vascular endothelial cells are changed, and tumor vessels are interdicted so as to make the tumor cells starved to death.
Owner:赤峰福纳康生物技术有限公司 +1
Alternating magnetic field thermotherapeutic system for tumor
InactiveCN1748814AReduce areaUniform magnetic fieldElectrotherapySurgical instruments for heatingMedical equipmentEngineering
The tumor treating thermotherapeutic alternate magnetic field system in medical equipment field includes alternate power source system, magnetic field generating system, magnetic path system thermotherapeutic temperature measuring and feeding back system, alternate magnetic field strength measuring and feeding back system, treating bed system, shielding system and central operation and control system. The alternate magnetic field system has power source output frequency of 1-500 KHz, magnetic conductor made of soft magnetic material of high magnetic conductivity, cross section area of the magnetic conductor gap in 10-1000 sq cm, fixed or adjustable gap of 5-60 cm, and magnetic field strength inside the gap of 1-50 kA / m. Owing to magnetic path system comprising magnetic conductor and gap, the treating part of the alternate magnetic field system has homogeneous magnetic field distribution, high heating efficiency and reasonable heating mode.
Owner:SHANGHAI ALLRUN NANO SCI & TECH
Acid-sensitive amphiphilic star-shaped block copolymer as well as preparation method and application thereof
InactiveCN103554508AOptimal Control StructureNarrow molecular weight distributionPharmaceutical non-active ingredientsPolyesterPolymer science
The invention discloses an acid-sensitive amphiphilic star-shaped block copolymer as well as a preparation method and application thereof. The preparation method comprises the steps of firstly, preparing a three-functional-group alkynyl compound with a benzene ring as a core by adopting condensation reaction; then, performing ring-opening polymerization on a cyclic ester monomer by taking a small molecule of which one end contains hydroxyl and the other end contains alkynyl as an initiating agent to obtain a polyester molecular chain, and modifying the polyester molecular chain into a polyester chain of which the tail end contains a chlorine functional group; then, modifying polyethylene glycol monomethyl ether into a molecular chain of which the tail end contains an aldehyde acetal group and an azide group; finally, preparing the acid-sensitive amphiphilic star-shaped block copolymer through two steps of 'CuAAC (Cu catalyzed azide-alkyne cycloaddition)' click reaction, wherein the polymer is controllable in structure and molecular weight and relatively narrow in molecular weight distribution and has good biocompatibility and biodegradability. The copolymer prepared by the invention can encapsulate a hydrophobic anticancer drug through self assembly, and under an acidic condition, due to the fracture of the aldehyde acetal group, a micelle structure is destroyed and an encapsulated drug is released, so that the copolymer can be used as a carrier for controlled release drugs.
Owner:SUZHOU UNIV
Bitarget fibroblast growth factor acceptor and transgene carrier of integrated element
InactiveCN1757738AGrowth inhibitionLow transfection efficiencyGenetic material ingredientsFermentationAbnormal tissue growthDisease
A transgenic carrier with deal targets (fibroblast growth factor receptor and integrant) is composed of the polypeptide CR16 specifically linked with alkaline fibroblast growth factor receptor, the polypeptide CP9 specifically linked with integrant, and the transgenic non-virus carrier system of CR16 / CP9 / cationic polymer PEI / exogenous DNA. Said carrier can effectively introduce the exogenous DNA to the tumor cell line and tumor tissue with high expression of FGFRs, so suppressing the growth of tumor. It can be used to preparation of the medicine for treating tumor and other diseases.
Owner:ZHEJIANG UNIV
Preparation method of tumor dendritic cell vaccine sensitized by glycosylated MUC1 (mucoprotein 1) antigen
InactiveCN103372205AEfficient activationIncrease intakeBlood/immune system cellsAntibody medical ingredientsSide effectImmune tolerance
The invention provides a preparation method of a tumor dendritic cell vaccine sensitized by glycosylated antigen MUC1 (mucoprotein 1). Glycosylation modified tumor antigen peptide is used for sensitizing externally cultured DC (Dendritic Cell) and then the activated DC cells are transfused to a tumor patient. The invention further provides an application of the tumor DC cell vaccine sensitized by the glycosylated MUC1 antigen in treatment of breast cancer and pancreatic cancer. The preparation method provided by the invention has the following advantages (1) the DC cell vaccine amplification efficiency is high; (2) the DC cells have high antigen activity; (3) the DC cells have high maturity degree, and side effects such as immune tolerance are prevented; and (4) small side effects are caused.
Owner:SHANGHAI FUHETAI BIOLOGICAL TECH CO LTD
Polyphosphoester-based folate-targeted acid-sensitive core-crosslinked drug-loaded micelle and preparation method thereof
ActiveCN104173282AStable structureGood biocompatibilityOrganic active ingredientsSolution deliveryTetraglycolFolate targeting
The invention discloses a polyphosphoester-based folate-targeted acid-sensitive core-crosslinked drug-loaded micelle and a preparation method thereof. The preparation method comprises the following steps: firstly, preparing an amphiphilic polyphosphoester segmented copolymer in a ring opening manner by adopting a one-pot method; modifying the terminal hydroxyl of the segmented copolymer to obtain a folate-modified segmented copolymer; then, modifying the hydroxyl on tetraglycol into a molecule of which the terminal contains aldehyde acetal group and azide group; and finally, preparing the acid sensitive core-crosslinked drug-loaded micelle by adopting a 'CuAAC' click reaction. The core-crosslinked micelle prepared by the method is capable of entrapping hydrophobic anticancer drugs by means of self-assembly and releasing the entrapped drugs because the broken aldehyde acetal group causes damage of the micelle structure under an acid condition, and can be used as a controlled drug release carrier. The core-crosslinked micelle disclosed by the invention can be used as an effective controlled release drug carrier, and has an excellent application value in the field of biomaterials and biomedicine.
Owner:SUZHOU UNIV
Polytheneimine transgened carrier of targeted fibroblast growth factor receptor
InactiveCN1614027AGrowth inhibitionLow transfection efficiencyGenetic material ingredientsOther foreign material introduction processesAbnormal tissue growthDisease
The invention was involved in the polymine modified vector of fibroblast growth factor receptor, containing peptide YC25 which could specially bind to the alkaline fibroblast growth factor receptor, peptide YC25 / positive ion PEI / exogenous DNA.The exogenous DNA could be effectively introduced to the cancer clone and system of high expression of FGFRs to inhibit the growth of tumor. But there was low effect to the tumor tissue and cell liens without expression of FGFRs, so the vector system was tumor-targeting. The non-virus vector system could transfer the exogenous DNA and its size ranged from tens bp to thousands kb to overcome the limit of the size of exogenous gene. So, it could be used to produce the medicament to cure tumor by combined transfer of multi-gene and also to produce gene drug for other disease.
Owner:ZHEJIANG UNIV
Obtainment of cell growth inhibiting polypeptide and its usage
InactiveCN1565621AInhibit phosphorylationIncreased ability to inhibit the cell cyclePeptide/protein ingredientsAntineoplastic agentsDiseaseWilms' tumor
The invention discloses a polypeptides making up of 25 amino acids, corresponding cDNA coded sequence, its preparation, the use of the peptide, its derivant and corresponding cDNA in treating tumor and other hyperplasia disease. The invention characterized in that it confirms that p55PIK protein with 25 amino acid in its amino end have key function in combining Rb, blocking Rb phosphorylation inside the cell, thus obtain a biological effect of inhibiting cell division. Making use of the peptide and transfecting corresponding cDNA and expressing the peptide inside the cell, can inhibit effectively cell growth and tumor growth. Meanwhile, the invention also discloses a novel method for blocking Rb phosphorylation process, and provides a novel method for manufacturing a tumor treating medicine.
Owner:WUHAN YICHENG BIOTECH CO LTD
Folic acid-targeted acid sensitive core-crosslinked drug-loaded micelles based on polyphosphoester
ActiveCN105832668AIncrease profitExtend cycle timeOrganic active ingredientsPharmaceutical non-active ingredientsTetraglycolBiological materials
Owner:SUZHOU UNIV
Application of long-chain non-coding RNA in preparation of tumor angiogenesis inhibitor
InactiveCN110123829AInhibition formationTumor cell growth inhibitoryOrganic active ingredientsAntineoplastic agentsTumor angiogenesisNon-coding RNA
The invention discloses application of long-chain non-coding RNA in the preparation of a tumor angiogenesis inhibitor. The influence and mechanism of a long-chain non-coding RNA gene on tumor angiogenesis are disclosed for the first time, tumor angiogenesis can be inhibited by influencing PDGFA level, and patients can be benefited during leukemia treatment.
Owner:SUZHOU UNIV
Antibody targeting Sirp alpha or antigen binding fragment of antibody as well as preparation and application of antibody or antigen binding fragment
PendingCN111635458AHigh binding activityFor the purpose of treating tumorsHybrid immunoglobulinsBacteriaAntigenHeavy chain
The invention discloses an antibody targeting Sirp alpha or an antigen binding fragment of the antibody. The antibody comprises a light chain variable region and / or a heavy chain variable region, theantibody or the antigen binding fragment thereof combines human Sirp alpha-V1 and human Sirp alpha-V2, but weakly combines or does not combine human Sirp beta and Sirp gamma, does not combine human Tcells, and has a function of blocking combination of Sirp alpha and CD47. The invention also discloses a bispecific antibody containing the antibody, and a preparation method and application of the antibody or the antigen binding fragment thereof. Due to the unique characteristics of the antibody or the antigen binding fragment thereof, the antibody or the antigen binding fragment thereof is moresuitable for drug development of the antibody or the antigen-binding fragment thereof aiming at the human Sirp alpha target, can be independently or jointly administrated as a candidate drug, and particularly provides a new or even better choice for combined immunotherapy of tumors.
Owner:L&L BIOPHARMA CO LTD
siRNA module of targeted Survivin gene and application thereof
ActiveCN101935651AInduce apoptosisInhibition of divisionGenetic material ingredientsAntineoplastic agentsAntisense RNASense strand
The invention relates to a siRNA module of targeted Survivin gene and application thereof in preparing tumor-resisting drugs. The siRNA molecule sense strand is shown in SEQ ID NO:2, and an antisense molecule is shown in SEQ ID NO:3; the antisense strand can be specifically combined with the mRNA of the Survivin gene to degrade the mRNA, thus interfering the posttranscriptional translation process to obtain the purpose of treating tumor.
Owner:BIOMICS BIOTECH
Research on antitumor mechanism of Combretastatin A-4 derivative
InactiveCN106727629AInhibit migrationInhibit phosphorylationOrganic active ingredientsAntineoplastic agentsVascular endotheliumFocal adhesion
The invention discloses and relates to the field of biomedicine, in particular to inhibition of Src-FAK (Src focal adhesion kinase) signal pathways by Combretastatin A-4 derivative CPU-TX-008 to inhibit VEGF-induced (vascular endothelial growth factor induced) migration of vascular endothelial cells. As a CA-4 (Combretastatin A-4) derivative, CPU-TX-008 is acquired by replacing hydroxy of CA-4 structure with more water-soluble glucosamine groups. In-vitro cell experiments show that the derivative plays a role in inhibiting the migration of HUVECs (human umbilical vein endothelial cells); it is discovered through the research on the influence of related migrated proteins Src and FAK that CPU-TX-008 inhibits cell migration by inhibiting the phosphorylation of Src and FAK proteins in HUVECs, finally inhibiting the growth of tumor vessels; by adding chemical groups to CA-4 to prepare tumor vessel inhibitory drugs, new clinical antitumor paths are provided.
Owner:CHINA PHARM UNIV
Use of siRNA in preparing medicament for regulating and controlling tumour cell division cycle
InactiveCN101456887ABroad-spectrum anti-tumor effectInhibition of divisionOrganic active ingredientsSugar derivativesCell division cycleOncology
The invention relates to application of a micromolecule interference RNA to the preparation of medicines capable of regulating and controlling the tumor cell division cycle. The micromolecule interference RNA can submerge the survivin gene expression, regulate and control the cell cycles of the lung cancer, the gastric cancer, the hepatic cancer, the breast cancer and the cervical carcinoma with high efficiency, and remarkably inhibit the division of the cells of the lung cancer, the gastric cancer, the hepatic cancer, the breast cancer and the cervical carcinoma. The micromolecule interference RNA can be used for preparing the medicines capable of inhibiting tumor cell division.
Owner:YICHUN UNIVERSITY
Polypeptide, polypeptide derivative, and polypeptide-antibody complex and preparation and application of polypeptide
InactiveCN110551177ASimple preparation processReduce manufacturing costMammal material medical ingredientsAntibody ingredientsBispecific antibodyT cell
The invention discloses a polypeptide, and belongs to the field of biomedicine. In order to solve the problems of complicated production process, high cost and low targeting existing in existing methods for enhancing the targeting of T cells, the invention provides the polypeptide. The polypeptide can significantly enhance the targeting of immune cells. At the same time, the preparation process ofthe polypeptide is simple, and the cost is lower than the existing cost of preparing CAR-T cells or the existing cost of preparing bispecific antibody cells.
Owner:安徽瑞达健康产业有限公司
Use of high efficiency siRNA for preparing drug capable of adjusting and controlling tumor cell cycle
InactiveCN101445538ABroad-spectrum anti-tumor effectInhibition of divisionOrganic active ingredientsSugar derivativesCell divisionOncology
The invention belongs to the biological medicine field, in particular relating to the use of a high efficiency small interfering RNA for preparing a drug capable of adjusting and controlling the tumor cell cycle. The high efficiency small interfering RNA can silence the expression of survivin, adjust and control the cycle of lung cancer, gastric cancer, liver cancer, breast cancer and cervical carcinoma cells, and obviously inhibit the division of the lung cancer, gastric cancer, liver cancer, breast cancer and cervical carcinoma cells. The small interfering RNA can also prepare the drug for inhibiting the division of the tumor cell.
Owner:YICHUN UNIVERSITY
Applications of human SAMD9L gene and protein product encoded by human SAMD9L gene
InactiveCN103571927AAccurate diagnosisRapid diagnosisPeptide/protein ingredientsMicrobiological testing/measurementOpen reading frameLymphatic Spread
The present invention discloses applications of human SAMD9L gene and a protein product encoded by the human SAMD9L gene, wherein the SAMD9L gene sequence, especially the open reading frame sequence of the protein encoded by the human SAMD9L gene, generates missense mutation, nonsense mutation, frameshift mutation and other gene structure variations with different forms in tumors so as to be adopted as the specific marker gene for liver cancer diagnosis, such that liver cancer diagnosis is accurate and rapid. According to the present invention, the human SAMD9L protein can be applied on tumor patients so as to treat or alleviate related diseases caused by SAMD9L protein deletion, nonfunction or abnormality; and the human SAMD9L gene can be over-expressed in cancer cells through the transgenic technology, or the SAMD9L protein can be supplied through the in vitro supply manner to control cancer cell proliferation and metastasis so as to achieve the tumor treatment purpose.
Owner:CHINESE NAT HUMAN GENOME CENT AT SHANGHAI
Self-assembled nano medicine-loaded micelle as well as preparation method and application thereof
InactiveCN110812327ALarge particle sizeAppropriate Score CoefficientOrganic active ingredientsPharmaceutical non-active ingredientsDimerTetrandrine
The present application provides a self-assembled nano medicine-loaded micelle as well as a preparation method and application thereof, and belongs to the technical fields of pharmaceutical preparations, polymer materials and nano materials. The preparation provided by the invention is a co-delivery reduction-sensitive nanomicelle drug delivery system prepared from a paclitaxel dimer prodrug, tetrandrine and an amphiphilic copolymer material. The synthesized drug provided by the invention is coated in a polymer material to prepare the nanomicelle. According to the method, a disulfide bond is introduced in the synthesis of the dimer prodrug, the tetrandrine can be firstly released to inhibit multidrug resistance caused by excessive P-glycoprotein in tumor cells, and the paclitaxel dimer isreduced into paclitaxel in a reducing environment in the tumor cells to inhibit the proliferation and division of the tumor cells and achieve the purpose of reversing the multidrug resistance of the tumor cells; and at the same time, the micelle particles provided by the invention are uniformly distributed and in a monodispersion state, and can realize a passive targeting effect in vivo and significantly increase the accumulation of the drug in cells.
Owner:YUNNAN UNIV
Application of HOXA9 gene in preparation of drugs for treatment of cutaneous squamous cell carcinoma
ActiveCN107475369AInhibit glycolysisInhibit migrationMicrobiological testing/measurementBiological testingExperimental researchSquamous Carcinomas
Belonging to the field of gene therapy, the invention discloses application of HOXA9 gene in preparation of drugs for treatment of cutaneous squamous cell carcinoma (CSCC). The inventor and the whole team carry out two years of experimental study, adopt cutaneous squamous cell carcinoma characteristic cell line A431 as the experimental object, and perform experiments to find that targeted up-regulation of HOXA9 can inhibit the tumor cell proliferation, migration and invasion ability, also can inhibit tumor cell glycolysis, and ultimately improve or treat cutaneous squamous cell carcinoma. The invention provides a new method for treatment of CSCC on the basis of maximum guarantee of complete organ functions and beautiful appearance, and the method can overcome the shortcomings of the existing technology and has great significance.
Owner:SOUTHERN MEDICAL UNIVERSITY
siRNA (Small interfering Ribonucleic Acid) molecule for interfering Survivin expression and application thereof
ActiveCN101935650AInduce apoptosisInhibition of divisionGenetic material ingredientsAntineoplastic agentsSense strandDouble stranded
The invention relates to a double-stranded siRNA molecule capable of interfering Survivin gene expression and application thereof to preparing an antitumor medicament. The positive-sense strand of the siRNA molecule is shown as SEQ ID NO:2, and the antisense strand thereof is shown as SEQ ID NO:3, wherein the antisense strand can be specifically combined with the mRNA (Messenger Ribonucleic Acid)of a Survivin gene for degrading the mRNA so as to interfere the translation process after transcription and achieve the purpose of treating tumor.
Owner:BIOMICS BIOTECH
Traditional Chinese medicine preparation for treating breast cancer
InactiveCN104623450AEasy to prepareEasy to takeUnknown materialsAntineoplastic agentsTrichosanthes kirilowiiAdiantum capillus-veneris
The invention discloses a traditional Chinese medicine preparation for treating breast cancer and a preparation method of the traditional Chinese medicine preparation. The traditional Chinese medicine preparation is prepared from the following main crude drugs in parts by mass: 13-20 parts of radix paeoniae alba, 2-4 parts of Indian iphigenia bulbs, 10-16 parts of ligotidis herba, 12-18 parts of raphani leaves, 8-13 parts of drymoglossum piloselloides, 7-12 parts of tangerine leaves, 15-20 parts of peperomia blanda, 16-25 parts of trichosanthes kirilowii, 11-19 parts of scabrousstem greenbrier rhizome, 14-20 parts of cottonrose hibiscus, 11-16 parts of four-leaf clovers, 6-14 parts of snake slough, 9-14 parts of adiantum capillus veneris and 10-17 parts of bittersweet herbs. The traditional Chinese medicine preparation is remarkable in curative effect, free of side effects, free of damage to an organism, capable of relieving the pain of a patient, prolonging the lifetime of the patient and improving the life quality of the patient, low in treatment cost, available in drug resource and low in price, and is easily accepted by the patient.
Owner:徐若曾
Protein nucleic acid compound, as well as preparation method and application thereof
PendingCN110790841AAvoid recognitionDodge clearPeptide/protein ingredientsPharmaceutical non-active ingredientsTissue factorThrombus
The invention provides a protein nucleic acid compound, as well as a preparation method and application thereof. The compound comprises a coagulation accelerator and a targeting molecule, wherein thecoagulation accelerator comprises a truncated tissue factor (tTF); the targeting molecule comprises a nucleic acid adapter; and the tTF and the nucleic acid adapter are connected through a coupling agent. The compound provided by the invention adopts the nucleic acid adapter as a tumor vessel targeting molecule, the tTF is specifically positioned on the surface of a tumor vessel wall surface, thrombogenesis is induced in a tumor vessel, and the blood supply of a tumor site and a discharge way of metabolic products are cut off, so that the safety is high, the immunogenicity is low, the recognition and the elimination of an immune system can be avoided, the specificity is high, and a tumor cell inhibition effect is achieved.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA
Small molecule interfering RNA and its anti-tumor use
InactiveCN101037688ABroad-spectrum anti-tumor effectInhibition of divisionOrganic active ingredientsSugar derivativesOpen reading frameTumor cell apoptosis
The invention relates to biological medicine field, concrete relates to a broad-spectrum small interfering RNA for survivin gene. The medicine designing double chain siRNA for function conservation of survivin gene open reading frame (ORF) has function of broad-spectrum antitumor and inhibition cariers of lung cancer, liver cancer, leukaemia, gastric cancer, cervical cancer, KB and so on, sense strand of the sequence combines with mRNA of survivin gene to disturb interprete thereof to induce apoptosis of tumour cells, to repress abruption thereof, to reduce drug fastness thereof, to repress generation of tumour vein to treatment tumour.
Owner:CHINA PHARM UNIV
Perfluorocarbon oxygen-carrying microsphere and preparation method and application thereof
InactiveCN110433143AWide variety of sourcesGood biocompatibilityInorganic active ingredientsPharmaceutical non-active ingredientsOxygen deficiencyChemistry
The present invention provides a perfluorocarbon oxygen-carrying microsphere and a preparation method and an application thereof. The preparation method comprises the following steps: preparing perfluorocarbon into an emulsion, oxygenating and disinfecting the perfluorocarbon emulsion which is soluble in water and can carry oxygen, wrapping the emulsion in carboxymethyl chitosan to form microspheres, and connecting folic acid on surfaces of the microspheres to realize a targeting function. The perfluorocarbon oxygen-carrying microsphere is applied in treatments of tumors and alleviation of hypoxia. The perfluorocarbon is used as an oxygen-carrying material and wrapped in the carboxymethyl chitosan, and then the folic acid molecules are grafted to form the microspheres with a core-shell structure. The microsphere can realize a slow release effect of oxygen, besides, the shell layer material has good biocompatibility and targeting property, so that the microsphere can relieve an oxygen deficiency problem of a tumor part, realizes a function of slowly releasing oxygen at an oxygen deficiency part, and achieves a purpose of treating tumors. The perfluorocarbon oxygen-carrying microsphere is simple in the preparation method and convenient to operate, and the prepared oxygen-carrying microsphere can be stored for a long time.
Owner:TONGJI UNIV
Traditional Chinese medicine composition for treating breast cancer
InactiveCN104623451AEasy to prepareEasy to takePowder deliveryPill deliveryTrichosanthes kirilowiiRadix Ophiopogonis
The invention discloses a traditional Chinese medicine composition for treating breast cancer and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following main raw materials in parts by mass: 13-19 parts of radix ophiopogonis, 9-14 parts of drymoglossum piloselloides, 8-15 parts of elaeocarpus hainanensis, 14-20 parts of trichosanthes kirilowii, 10-18 parts of scabrousstem greenbrier rhizome, 13-18 parts of cottonrose hibiscus, 12-16 parts of livistona chinensis, 7-16 parts of Chinese catalpa barks, 11-18 parts of peperomia blanda, 10-17 parts of wolfberries, 8-17 parts of Chinese brake herbs, 14-21 parts of radix paeoniae alba, 6-15 parts of macaranga tanarius and 12-18 parts of roses. The traditional Chinese medicine preparation is remarkable in curative effect, free of side effects, free of damage to an organism, capable of relieving the pain of a patient, prolonging the lifetime of the patient and improving the life quality of the patient, low in treatment cost, available in drug resource and low in price, and is easily accepted by the patient.
Owner:徐若曾
SiRNA (Small Interfering RNA) molecule capable of suppressing Survivin expression and application thereof
ActiveCN101935649AInduce apoptosisInhibition of divisionGenetic material ingredientsAntineoplastic agentsSense strandWilms' tumor
The invention relates to a double-stranded siRNA (Small Interfering RNA) molecule capable of suppressing Survivin expression and application thereof in preparing antitumor drugs. The siRNA molecule has a positive-sense strand of SEQ ID NO:2 and an antisense strand of SEQ ID NO:3, wherein the antisense strand can specifically combine with mRNA (Messenger RNA) of a Survivin gene to degrade the mRNA so as to interfere a transcription posttranslational process, therefore the purpose of treating tumors is achieved.
Owner:BIOMICS BIOTECH
Micromolecular methyl ethyl ketone (MEK) protein kinase inhibitor
InactiveCN102358730AReach treatmentFor the purpose of treating tumorsOrganic active ingredientsNervous disorderDiseasePTK Inhibitors
The invention discloses a micromolecular methyl ethyl ketone (MEK) protein kinase inhibitor, a preparation method of the MEK protein kinase inhibitor and applications of the MEK protein kinase inhibitor in preparation of medicaments for treating diseases such as tumors, rheumatic arthritis and the like.
Owner:JINAN SAIWEN PHARMTECH +1
Structure of siRNA for target survivin gene and antineoplastic usage
InactiveCN101041679ABroad-spectrum anti-tumor effectInhibition of divisionOrganic active ingredientsSugar derivativesOpen reading frameWilms' tumor
The invention discloses a micro-molecular interference RNA (siRNA) structure and tumour-proof utility of target dying inhibiting gene surviving, which is characterized by the following: designing double-chain siRNA of functional conserving area of ORF to inhibit tumour such as lung carcinoma, liver cancer and leukemia cell; connecting positive-meaning chain of CPUsiRNA2 and mRNA of surviving; interfering the interpretation after transcription; inducing cell to dye for tumour cell; inhibiting cell from splitting; reducing the drug tolerance of tumour cell.
Owner:CHINA PHARM UNIV
Tumor cell sugar uptake inhibitor and application thereof
ActiveCN108359671AInhibitionInhibit progressOrganic active ingredientsFermentationWilms' tumorLeukaemia cell
The invention discloses a tumor cell sugar uptake inhibitor and application thereof. The invention discloses for the first time the influence and mechanism of a long-chain non-coding RNA gene on the tumor cell sugar uptake; the tumor cell sugar uptake can be inhibited by affecting the GLUT10 level; the energy source of leukemia cells is effectively blocked, so that patients can benefit from the treatment of leukemia.
Owner:SUZHOU UNIV
Nanometer material as well as preparation method and application thereof
ActiveCN109675061AGood dispersionEasy to manufactureEnergy modified materialsGeneral/multifunctional contrast agentsBiocompatibility TestingTherapeutic effect
The invention relates to the field of nanoscale biomedical materials, in particular to a nanometer material as well as a preparation method and application thereof. The nanometer material comprises BSA: RE1, an RE2 inner core, a PDA shell layer covering the surfaces of the BSA: RE1 and the RE2 inner core, and FA on the surface of PDA, where RE1 and RE2 are different. The nanometer material has good dispersibility, is easy to prepare, has excellent biocompatibility and safety, can accurately perform multimodal MRI / CT imaging on tumors, and has a good photothermal treatment effect on the tumors.
Owner:INST OF SPECIAL ANIMAL & PLANT SCI OF CAAS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com